Entera Bio (ENTX) Total Non-Current Liabilities (2017 - 2026)
Entera Bio (ENTX) posted quarterly Total Non-Current Liabilities of $866000.0 for Q1 2026, up 44.82% year-on-year from $598000.0 in Q1 2025, and up 25.69% on a QoQ basis from $689000.0 in Q4 2025.
Entera Bio (ENTX) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has reported Total Non-Current Liabilities for 10 consecutive years, with $866000.0 the latest figure, recorded in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 44.82% year-over-year to $866000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $866000.0 (up 44.82% YoY) and the FY2025 annual result came in at $689000.0, up 414.18% from the prior year.
- Total Non-Current Liabilities improved to $866000.0 in Q1 2026 per ENTX's latest filing, from $689000.0 in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ENTX reached as high as $866000.0 in Q1 2026 and fell as low as $32000.0 in Q4 2022.
- A 5-year average of $323235.3 and a median of $255000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities tumbled 87.74% — and 2023, when it soared 800.0%.
- Year by year, Total Non-Current Liabilities stood at $32000.0 in 2022, then surged by 800.0% to $288000.0 in 2023, then plunged by 53.47% to $134000.0 in 2024, then surged by 414.18% to $689000.0 in 2025, then climbed by 25.69% to $866000.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $866000.0, $689000.0, and $602000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 746.94 Mn |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - | 866,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 866,000.00 |
| Dec 31, 2025 | 689,000.00 |
| Sep 30, 2025 | 602,000.00 |
| Jun 30, 2025 | 567,000.00 |
| Mar 31, 2025 | 598,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Sep 30, 2024 | 178,000.00 |
| Jun 30, 2024 | 209,000.00 |
| Mar 31, 2024 | 255,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | 302,000.00 |
| Jun 30, 2023 | 348,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Dec 31, 2022 | 32,000.00 |
| Sep 30, 2022 | 35,000.00 |
| Jun 30, 2022 | 127,000.00 |
| Mar 31, 2022 | 233,000.00 |
| Dec 31, 2021 | 261,000.00 |
| Jun 30, 2021 | 275,000.00 |
| Dec 31, 2020 | 371,000.00 |